記住我
Psychotherapy and Psychosomatics
Kou J.a,b· Zhang Y.a,c· Zhou F.a· Gao Z.a· Yao S.a· Zhao W.a· Li H.b· Lei Y.b· Gao S.a· Kendrick K.M.a· Becker B.aaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China
bInstitute of Brain and Psychological Sciences, Sichuan Normal University, Chengdu, China
cDepartment of Molecular Psychology, Institute of Psychology and Education, Ulm University, Ulm, Germany
Log in to MyKarger to check if you already have access to this content.
Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price. Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication DetailsFirst-Page Preview
Received: July 03, 2021
Accepted: November 29, 2021
Published online: January 27, 2022
Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 1
ISSN: 0033-3190 (Print)
eISSN: 1423-0348 (Online)
For additional information: https://www.karger.com/PPS
AbstractIntroduction: Anxiety disorders are prevalent mental conditions characterized by exaggerated anxious arousal and threat reactivity. Animal and human studies suggest an anxiolytic potential of the neuropeptide oxytocin (OT), yet, while a clinical application will require chronic administration protocols, previous human studies have exclusively focused on single-dose (acute) intranasal OT effects. Objective: To facilitate the translation of the potential anxiolytic mechanism of OT into clinical application, we determined whether the anxiolytic effects of OT are maintained with repeated (chronic) administration or are influenced by dose frequency and trait anxiety. Methods: In a pre-registered double-blind randomized placebo-controlled pharmaco-fMRI trial the acute (single dose) as well as chronic effects of two different dose frequencies of OT (OT administered daily for 5 days or every other day) on emotional reactivity were assessed in n = 147 individuals with high versus low trait anxiety (ClinicalTrials.gov ID: NCT03085654). Results: OT produced valence, dose frequency, and trait anxiety-specific effects, such that the low-frequency (intermittent) chronic dosage specifically attenuated a neural reactivity increase in amygdala-insula-prefrontal circuits observed in the high anxious placebo-treated subjects in response to threatening but not positive stimuli. Conclusions: The present trial provides the first evidence that low-dose frequency chronic intranasal OT has the potential to alleviate exaggerated neural threat reactivity in subjects with elevated anxiety levels, suggesting a treatment potential for anxiety disorders.
© 2022 S. Karger AG, Basel
References Sussman TJ, Jin J, Mohanty A. Top-down and bottom-up factors in threat-related perception and attention in anxiety. Biol Psychol. 2016 Dec;121:160–72. Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) Surveys. Epidemiol Psichiatr Soc. 2009;18(1):23–33. Blanco C, Bragdon LB, Schneier FR, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2013 Feb;16(1):235–49. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502–14. Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry. 2016 Feb;79(3):213–21. Zhou F, Geng Y, Xin F, Li J, Feng P, Liu C, et al. Human extinction learning is accelerated by an angiotensin antagonist via ventromedial prefrontal cortex and its connections with basolateral amygdala. Biol Psychiatry. 2019 Dec;86(12):910–20. Calhoon GG, Tye KM. Resolving the neural circuits of anxiety. Nat Neurosci. 2015 Oct;18(10):1394–404. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007 Oct;164(10):1476–88. Robinson OJ, Pike AC, Cornwell B, Grillon C. The translational neural circuitry of anxiety. J Neurol Neurosurg Psychiatry. 2019;90(12):1353–60. Tovote P, Fadok JP, Lüthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci. 2015 Jun;16(6):317–31. Xu X, Dai J, Chen Y, Liu C, Xin F, Zhou X, et al. Intrinsic connectivity of the prefrontal cortex and striato-limbic system respectively differentiate major depressive from generalized anxiety disorder. Neuropsychopharmacol. 2021 Mar;46(4):791–8. Zhao Z, Yao S, Li K, Sindermann C, Zhou F, Zhao W, et al. Real-time functional connectivity-informed neurofeedback of amygdala-frontal pathways reduces anxiety. Psychother Psychosom. 2019;88(1):5–15. Chavanne AV, Robinson OJ. The overlapping neurobiology of induced and pathological anxiety: a meta-analysis of functional neural activation. Am J Psychiatry. 2021 Feb;178(2):156–64. Brehl AK, Kohn N, Schene AH, Fernández G. A mechanistic model for individualised treatment of anxiety disorders based on predictive neural biomarkers. Psychol Med. 2020 Apr;50(5):727–36. De Cagna F, Fusar-Poli L, Damiani S, Rocchetti M, Giovanna G, Mori A, et al. The role of intranasal oxytocin in anxiety and depressive disorders: a systematic review of randomized controlled trials. Clin Psychopharmacol Neurosci. 2019 Feb;17(1):1–11. Gorka SM, Young CB, Klumpp H, Kennedy AE, Francis J, Ajilore O, et al. Emotion-based brain mechanisms and predictors for SSRI and CBT treatment of anxiety and depression: a randomized trial. Neuropsychopharmacol. 2019 Aug;44(9):1639–48. Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron. 2012 Feb;73(3):553–66. Hasan MT, Althammer F, Silva da Gouveia M, Goyon S, Eliava M, Lefevre A, et al. A fear memory engram and its plasticity in the hypothalamic oxytocin system. Neuron. 2019 Jul;103(1):133–46.e8. Ayers LW, Missig G, Schulkin J, Rosen JB. Oxytocin reduces background anxiety in a fear-potentiated startle paradigm: peripheral vs central administration. Neuropsychopharmacology. 2011 Nov;36(12):2488–97. Triana-Del Río R, van den Burg E, Stoop R, Hegoburu C. Acute and long-lasting effects of oxytocin in cortico-limbic circuits: consequences for fear recall and extinction. Psychopharmacology. 2019 Jan;236(1):339–54. Toth I, Neumann ID, Slattery DA. Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner. Psychopharmacology. 2012 Sep;223(2):149–58. Lee MR, Shnitko TA, Blue SW, Kaucher AV, Winchell AJ, Erikson DW, et al. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nat Commun. 2020 Jun;11(1):2783. Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2021;26(1):80–91. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005 Dec;25(49):11489–93. Xin F, Zhou X, Dong D, Zhao Z, Yang X, Wang Q, et al. Oxytocin differentially modulates amygdala responses during top-down and bottom-up aversive anticipation. Adv Sci. 2020;7(16):2001077. Eckstein M, Becker B, Scheele D, Scholz C, Preckel K, Schlaepfer TE, et al. Oxytocin facilitates the extinction of conditioned fear in humans. Biol Psychiatry. 2015 Aug;78(3):194–202. Striepens N, Scheele D, Kendrick KM, Becker B, Schäfer L, Schwalba K, et al. Oxytocin facilitates protective responses to aversive social stimuli in males. PNAS. 2012 Oct;109(44):18144–9. Yao S, Becker B, Zhao W, Zhao Z, Kou J, Ma X, et al. Oxytocin modulates attention switching between interoceptive signals and external social cues. Neuropsychopharmacol. 2018 Jan;43(2):294–301. Gottschalk MG, Domschke K. Oxytocin and anxiety disorders. Curr Top Behav Neurosci. 2018 Jan;35:467–98. Gorka S, Fitzgerald D, Labuschagne I, Hosanagar A, Wood A, Nathan P, et al. Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder. Neuropsychopharmacol. 2015 Jan;40(2):278–86. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacol. 2010 Nov;35(12):2403–13. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, et al. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol. 2012 Aug;15(7):883–96. Peters S, Slattery DA, Uschold-Schmidt N, Reber SO, Neumann ID. Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice. Psychoneuroendocrinology. 2014 Apr;42:225–36. Winter J, Meyer M, Berger I, Peters S, Royer M, Bianchi M, et al. Chronic oxytocin-driven alternative splicing of CRFR2α induces anxiety. bioRxiv. 2020 Aug. Pisansky MT, Hanson LR, Gottesman II, Gewirtz JC. Oxytocin enhances observational fear in mice. Nat Commun. 2017 Dec;8(1):2102. Slattery DA, Neumann ID. Chronic ICV oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology. 2010 Jan;58(1):56–61. del Razo RA, Berger T, Conley AJ, Freeman SM, Goetze LR, Jacob S, et al. Effects of chronic intranasal oxytocin on behavior and cerebral glucose uptake in juvenile titi monkeys. Psychoneuroendocrinology. 2020 Mar;113:104494. Kou J, Zhang Y, Zhou F, Sindermann C, Montag C, Becker B, et al. A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin. Psychol Med. 2020 Dec:1–10. Alvares GA, Chen NT, Balleine BW, Hickie IB, Guastella AJ. Oxytocin selectively moderates negative cognitive appraisals in high trait anxious males. Psychoneuroendocrinology. 2012 Dec;37(12):2022–31. Schumacher S, Oe M, Wilhelm FH, Rufer M, Heinrichs M, Weidt S, et al. Does trait anxiety influence effects of oxytocin on eye-blink startle reactivity? A randomized, double-blind, placebo-controlled crossover study. PLoS One. 2018 Jan;13(1):e0190809. Poldrack RA, Baker CI, Durnez J, Gorgolewski KJ, Matthews PM, Munafò MR, et al. Scanning the horizon: towards transparent and reproducible neuroimaging research. Nat Rev Neurosci. 2017 Feb;18(2):115–26. Spengler FB, Schultz J, Scheele D, Essel M, Maier W, Heinrichs M, et al. Kinetics and dose dependency of intranasal oxytocin effects on amygdala reactivity. Biol Psychiatry. 2017 Dec;82(12):885–94. Martins DA, Mazibuko N, Zelaya F, Vasilakopoulou S, Loveridge J, Oates A, et al. Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans. Nat Commun. 2020 Dec;11(1):1160. Quintana DS, Westlye LT, Alnæs D, Rustan ØG, Kaufmann T, Smerud KT, et al. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: a peripheral effect-controlled within-subjects randomized dose-response fMRI trial. Psychoneuroendocrinology. 2016 Jul;69:180–8. Horta M, Kaylor K, Feifel D, Ebner NC. Chronic oxytocin administration as a tool for investigation and treatment: a cross-disciplinary systematic review. Neurosci Biobehav Rev. 2020 Jan;108:1–23. Ironside M, Browning M, Ansari TL, Harvey CJ, Sekyi-Djan MN, Bishop SJ, et al. Effect of prefrontal cortex stimulation on regulation of amygdala response to threat in individuals with trait anxiety: a randomized clinical trial. JAMA Psychiatry. 2019 Jan;76(1):71–8. Kvaal K, Ulstein I, Nordhus IH, Engedal K. The Spielberger State-Trait Anxiety Inventory (STAI): the state scale in detecting mental disorders in geriatric patients. Int J Geriatr Psychiatry. 2005 Jul;20(7):629–34. Charpentier CJ, Aylward J, Roiser JP, Robinson OJ. Enhanced risk aversion, but not loss aversion, in unmedicated pathological anxiety. Biol Psychiatry. 2017 Jun;81(12):1014–22. Lieberz J, Scheele D, Spengler FB, Matheisen T, Schneider L, Stoffel-Wagner B, et al. Kinetics of oxytocin effects on amygdala and striatal reactivity vary between women and men. Neuropsychopharmacol. 2020 Jun;45(7):1134–40. Engel S, Klusmann H, Ditzen B, Knaevelsrud C, Schumacher S. Menstrual cycle-related fluctuations in oxytocin concentrations: a systematic review and meta-analysis. Front Neuroendocrinol. 2019 Jan;52:144–55. Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM, et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology. 2013 May;38(5):612–25. Eckstein M, Markett S, Kendrick KM, Ditzen B, Liu F, Hurlemann R, et al. Oxytocin differentially alters resting state functional connectivity between amygdala subregions and emotional control networks: inverse correlation with depressive traits. NeuroImage. 2017 Apr;149:458–67. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clinical Psychology Review. 1988 Jan;8(1):77–100. Marchewka A, Zurawski Ł, Jednoróg K, Grabowska A. The Nencki Affective Picture System (NAPS): introduction to a novel, standardized, wide-range, high-quality, realistic picture database. Behav Res Methods. 2014 Jun;46(2):596–610. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1994;2(4):189–210. Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The human Brainnetome Atlas: a new brain atlas based on connectional architecture. Cereb Cortex. 2016 Aug;26(8):3508–26. Mylius V, Ayache SS, Ahdab R, Farhat WH, Zouari HG, Belke M, et al. Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: inter-rater reliability, accuracy, and influence of gender and age. NeuroImage. 2013 Sep;78:224–32. Kreuder A-K, Scheele D, Schultz J, Hennig J, Marsh N, Dellert T, et al. Common and dissociable effects of oxytocin and lorazepam on the neurocircuitry of fear. PNAS. 2020 May;117(21):11781–7. Grillon C, Krimsky M, Charney DR, Vytal K, Ernst M, Cornwell B. Oxytocin increases anxiety to unpredictable threat. Mol Psychiatry. 2013 Sep;18(9):958–60. Kanat M, Heinrichs M, Schwarzwald R, Domes G. Oxytocin attenuates neural reactivity to masked threat cues from the eyes. Neuropsychopharmacol. 2015 Jan;40(2):287–95. Radke S, Volman I, Kokal I, Roelofs K, de Bruijn ERA, Toni I. Oxytocin reduces amygdala responses during threat approach. Psychoneuroendocrinology. 2017 May;79:160–6. Yao S, Zhao W, Geng Y, Chen Y, Zhao Z, Ma X, et al. Oxytocin facilitates approach behavior to positive social stimuli via decreasing anterior insula activity. Int J Neuropsychopharmacol. 2018 Oct;21(10):918–25. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011 Jul;15(7):301–9. Shamay-Tsoory SG, Abu-Akel A. The social salience hypothesis of oxytocin. Biol Psychiatry. 2016 Feb;79(3):194–202. Xu X, Li J, Chen Z, Kendrick KM, Becker B. Oxytocin reduces top-down control of attention by increasing bottom-up attention allocation to social but not non-social stimuli: a randomized controlled trial. Psychoneuroendocrinology. 2019 Oct;108:62–9. Stein MB, Simmons AN, Feinstein JS, Paulus MP. Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. Am J Psychiatry. 2007 Feb;164(2):318–27. Bruce SE, Buchholz KR, Brown WJ, Yan L, Durbin A, Sheline YI. Altered emotional interference processing in the amygdala and insula in women with post-traumatic stress disorder. Neuroimage Clin. 2013 Jan;2:43–9. Quirk GJ, Likhtik E, Pelletier JG, Paré D. Stimulation of medial prefrontal cortex decreases the responsiveness of central amygdala output neurons. J Neurosci. 2003 Sep;23(25):8800–7. Ironside M, O'Shea J, Cowen PJ, Harmer CJ. Frontal cortex stimulation reduces vigilance to threat: implications for the treatment of depression and anxiety. Biol Psychiatry. 2016 May;79(10):823–30. Wheelock MD, Sreenivasan KR, Wood KH, Ver Hoef LW, Deshpande G, Knight DC. Threat-related learning relies on distinct dorsal prefrontal cortex network connectivity. NeuroImage. 2014 Nov;102(Pt 2):904–12. Sarinopoulos I, Grupe DW, Mackiewicz KL, Herrington JD, Lor M, Steege EE, et al. Uncertainty during anticipation modulates neural responses to aversion in human insula and amygdala. Cerebral Cortex. 2010 Apr;20(4):929–40. Straube T, Mentzel HJ, Miltner WH. Waiting for spiders: brain activation during anticipatory anxiety in spider phobics. NeuroImage. 2007 Oct;37(4):1427–36. Du P, He Z, Cai Z, Hao X, Dong N, Yuan W, et al. Chronic central oxytocin infusion impairs sociability in mandarin voles. Pharmacol Biochem Behav. 2017 Oct;161:38–46. Lohse MJ, Hofmann KP. Spatial and temporal aspects of signaling by G-protein-coupled receptors. Mol Pharmacol. 2015 Sep;88(3):572–8. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002 Sep;3(9):639–50. Tops M, Huffmeijer R, Linting M, Grewen K, Light K, Koole S, et al. The role of oxytocin in familiarization-habituation responses to social novelty. Front Psychol. 2013;4:761. De Dreu CK, Baas M, Boot NC. Oxytocin enables novelty seeking and creative performance through upregulated approach: evidence and avenues for future research. Wiley Interdiscip Rev Cogn Sci. 2015;6(5):409–17. Williams VS, Morlock RJ, Feltner D. Psychometric evaluation of a visual analog scale for the assessment of anxiety. Health Qual Life Outcomes. 2010 Jun;8(1):57. Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of ethanol like effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry. 1994 Nov;51(11):898–911. de Oliveira DC, Zuardi AW, Graeff FG, Queiroz RH, Crippa JA. Anxiolytic-like effect of oxytocin in the simulated public speaking test. J Psychopharmacol. 2012 Apr;26(4):497–504. Carrozzino D, Patierno C, Guidi J, Berrocal Montiel C, Cao J, Charlson ME, et al. Clinimetric criteria for patient-reported outcome measures. Psychother Psychosom. 2021;90(4):222–32. Bargh J. The four horsemen of automaticity: awareness, efficiency, intentions and control. In: Wyer R, Srull T, editors. Handbook of social cognition. Mahwah: Lawrence Erlbaum; 1994. p. 1040. Nosek BA. Implicit-explicit relations. Curr Dir Psychol Sci. 2007 Apr;16(2):65–9. Tully J, Gabay AS, Brown D, Murphy DGM, Blackwood N. The effect of intranasal oxytocin on neural response to facial emotions in healthy adults as measured by functional MRI: a systematic review. Psychiatry Res Neuroimaging. 2018 Feb;272:17–29. Olivera-Pasilio V, Dabrowska J. Oxytocin promotes accurate fear discrimination and adaptive defensive behaviors. Front Neurosci. 2020 Sep;14:583878. Bar-Haim Y, Lamy D, Pergamin L, Bakermans-Kranenburg MJ, van IJzendoorn MH. Threat-related attentional bias in anxious and nonanxious individuals: a meta-analytic study. Psychol Bull. 2007;133(1):1–24. Knowles KA, Olatunji BO. Specificity of trait anxiety in anxiety and depression: meta-analysis of the State-Trait Anxiety Inventory. Clin Psychol Rev. 2020 Dec;82:101928. Schiele MA, Thiel C, Kollert L, Fürst L, Putschin L, Kehle R, et al. Oxytocin receptor gene DNA methylation: a biomarker of treatment response in obsessive-compulsive disorder? Psychother Psychosom. 2021;90(1):57–63. Article / Publication DetailsFirst-Page Preview
Received: July 03, 2021
Accepted: November 29, 2021
Published online: January 27, 2022
Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 1
ISSN: 0033-3190 (Print)
eISSN: 1423-0348 (Online)
For additional information: https://www.karger.com/PPS
Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
留言 (0)